|
Dr. Johann de
Bono MD FRCP MSc PhD was appointed in July 2003, as Senior Lecturer and
Honorary Consultant in Medical Oncology at the Royal
Marsden Hospital
and Institute of Cancer
Research, which form Europe's
largest Comprehensive Cancer Centre. Dr. de Bono works in the clinical drug
development Phase I trials program at the Royal Marsden
Hospital with a
particular interest in the rationally designed molecular targeted therapies and
prostate cancer.
He graduated in
medicine from the University of Glasgow in Scotland in 1989, and trained in
internal medicine, graduating as a Member of the Royal College of Physicians
(MRCP) in 1992. He was then awarded a four-year Cancer Research UK Clinical
Research Scholarship, which allowed him to pursue a PhD.
He then trained
in medical oncology, and was awarded a Masters degree in oncology in 1999 by Glasgow University. The Royal College of
Physicians then awarded him a travelling scholarship, which allowed him to
pursue further research in 2000 on the statistical issues that pertain to
clinical trials of targeted drugs, at the SWOG statistical headquarters at the
Fred Hutton Cancer Centre in Seattle,
USA. Following
this, he pursued further research, developing new anticancer drugs in the USA at the Institute for Drug Development in San Antonio and the University
of Texas Health Science Centre at San Antonio. Dr. de Bono
worked in this institution between 2000 and 2003. He was elected FRCP in 2003.
He has received
many awards during his career including the American Society for Clinical
Oncology (ASCO) Young Investigator Award, an ASCO Merit Award, a Doris Duke
Charitable Foundation Clinician-Scientist Faculty Award and Berlex Oncology
Foundation Award. He has been awarded research grants from the Cancer Research
Campaign, the Medical Research Council, the US National Institute of Health,
the American Association of Cancer Research, the Federation of European Cancer
Societies, the American Society of Clinical Oncology, the Doris Duke Charitable
Foundation and the Mesothelioma Applied Research Foundation.
Dr. de Bono has
been involved in the development of over 50 novel agents over the last 5-years,
many of which are now approved drugs. He is currently running over 20 early
clinical trials.
|
